In the Reduction of Endpoints in noninsulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial, patients treated with losartan were 2.8 times more likely to develop hyperkalemia (≥5.0 mmol/L) at six months than those not treated with losartan, and hyperkalemia (≥5.0 mmol/L) at six months were associated with a 22% higher risk of doubling of the serum creatinine level or for ESKD, after the adjustment for relevant factors [50]. This evidence concerns the gene AGT and Hyperkalemia.